FDA advances work related to cannabidiol products with focus on protecting public health, providing market clarity
from U.S. Food & Drug Administration
Over the past year, the U.S. Food and Drug Administration has embarked on a comprehensive evaluation of cannabidiol (CBD) products, with a focus on educating the public about the risks and unknowns of these products, gathering the science needed to better understand both these safety concerns and potential benefits to inform our regulatory approach, as well as taking steps when necessary to address products that violate the law in ways that raise a variety of public health concerns.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063